Skip to main content
Hemogenyx Pharmaceuticals Plc (LON:HEMO)
London flag London · Delayed Price · Currency is GBP · Price in GBX
690.00
-113.00 (-14.07%)
Apr 28, 2026, 5:07 PM GMT

Hemogenyx Pharmaceuticals Income Statement

Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
 Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
4.514.745.824.972.582.04
Upgrade
Operating Expenses
5.215.386.475.532.72.15
Upgrade
Operating Income
-5.21-5.38-6.47-5.53-2.7-2.15
Upgrade
Interest Expense
-0.25-0.27-0.32-0-1.39-0.03
Upgrade
Interest & Investment Income
0.010.020.090.010.020
Upgrade
Currency Exchange Gain (Loss)
-2.36--1.53--
Upgrade
Other Non Operating Income (Expenses)
----0.10.09
Upgrade
EBT Excluding Unusual Items
-7.82-5.63-6.7-3.99-3.97-2.1
Upgrade
Other Unusual Items
-----1.14-
Upgrade
Pretax Income
-7.82-5.63-6.7-3.99-5.11-2.1
Upgrade
Earnings From Continuing Operations
-7.82-5.63-6.7-3.99-5.11-2.1
Upgrade
Minority Interest in Earnings
0.010.010.010.010.010.01
Upgrade
Net Income
-7.81-5.62-6.69-3.98-5.1-2.08
Upgrade
Net Income to Common
-7.81-5.62-6.69-3.98-5.1-2.08
Upgrade
Shares Outstanding (Basic)
433221
Upgrade
Shares Outstanding (Diluted)
433221
Upgrade
Shares Change (YoY)
15.82%16.95%15.25%26.59%86.57%15.00%
Upgrade
EPS (Basic)
-2.21-1.70-2.37-1.62-2.64-2.01
Upgrade
EPS (Diluted)
-2.21-1.70-2.37-1.62-2.64-2.01
Upgrade
Free Cash Flow
-5.59-4.15-6.22-3.34-3.26-1.97
Upgrade
Free Cash Flow Per Share
-1.58-1.26-2.20-1.36-1.69-1.90
Upgrade
EBITDA
-4.98-5.15-6.24-5.44-2.61-2.08
Upgrade
D&A For EBITDA
0.230.230.230.090.090.07
Upgrade
EBIT
-5.21-5.38-6.47-5.53-2.7-2.15
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.